Silex Systems Limited
A.B.N.69 003 372 067

Level 8, Suite 8.01
56 Clarence Street
Sydney NSW 2000 Australia

PO Box 364
Sydney NSW 2001

Tel: + 61 2 9704 8888
Fax: +61 2 9279 1051
www.silex.com.au

WEBCAST OF ANNUAL GENERAL MEETING

18th NOVEMBER 2015

Speaker: Dr Michael Goldsworthy, CEO and Managing Director

Live date: Tuesday, 17th November 2015 9.30am AEDT

Access this webcast at: http://www.openbriefing.com/OB/1990.aspx

Further information on the Company's activities can be found on the Silex website: www.silex.com.au or by contacting the persons listed below on +61 2 9704 8888:

- Michael Goldsworthy, CEO / Managing Director; or
- Julie Ducie, CFO / Company Secretary.

About Silex Systems Limited:

Silex Systems Limited (ASX: SLX) (OTCQX: SILXY) ("Silex") is an Australian high-tech company focused on the delivery of its unique and disruptive 'SILEX' laser enrichment technology as the next generation technology for the global uranium enrichment industry. The SILEX Technology has been exclusively licensed to GE-Hitachi Global Laser Enrichment, a business venture of GE (51%), Hitachi (25%) and Cameco (24%) based in Wilmington, North Carolina.

Until recently, Silex also had active interests in solar and semiconductor technologies. Under a restructure announced by the Silex Board in June 2014, a divestment process has been undertaken in order to return the Company's focus to the SILEX Technology. For more information, refer to the Silex website at: www.silex.com.au.

Forward Looking Statements and Business Risks:

Silex Systems is a research and development Company whose assets are its proprietary rights in various technologies, including, but not limited to, the SILEX technology, Solar Systems technology, and Translucent technology. Several of the Company's technologies are in the development stage and have not been commercially deployed, and therefore are high-risk. Accordingly, the statements in this announcement regarding the future of the Company's technologies and commercial prospects are forward looking and actual results could be materially different from those expressed or implied by such forward looking statements as a result of various risk factors.

Some risk factors that could affect future results and commercial prospects include, but are not limited to: results from the SILEX uranium enrichment commercialisation program; the demand for enriched uranium; the outcomes of the Company's interests in the development of various semiconductor and alternative energy technologies; the time taken to develop various technologies; the development of competing technologies; the potential for third party claims against the Company's ownership of Intellectual Property associated with its numerous technologies; the potential impact of government regulations or policies; and the outcomes of various commercialisation strategies undertaken by the Company.